Journal rankings · indicator year 2006
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2006
Oncology journal rankings 2006
120 ranked journals · Subfield in Medicine
Oncology has 120 ranked journals in 2006. The median journal has an OJR of 0.85, below the world average of 1.00, up 0.02 on 2005; Q1 starts at OJR 1.25. The top three are CA A Cancer Journal for Clinicians, Cancer Cell, and Nature Medicine.
Ranks and citation indicators: 2006. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2003–2005, the window the 2006 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery428
- Pulmonary and Respiratory Medicine181
- Public Health, Environmental and Occupational Health154
- Cardiology and Cardiovascular Medicine150
- Oncology120
- Epidemiology97
- Infectious Diseases95
- Psychiatry and Mental health89
- Radiology, Nuclear Medicine and Imaging86
- Neurology82
- Endocrinology, Diabetes and Metabolism78
- Physiology75
Show all 42 subfields
- Orthopedics and Sports Medicine54
- Pediatrics, Perinatology and Child Health54
- Dermatology51
- Hematology48
- Ophthalmology48
- Obstetrics and Gynecology41
- Rheumatology37
- Nephrology34
- Pharmacology29
- Complementary and alternative medicine27
- Reproductive Medicine27
- Emergency Medicine24
- Geriatrics and Gerontology23
- Otorhinolaryngology18
- Rehabilitation18
- Pathology and Forensic Medicine17
- Critical Care and Intensive Care Medicine14
- Immunology and Allergy12
- Genetics9
- Hepatology9
- Anesthesiology and Pain Medicine8
- Urology7
- Gastroenterology6
- Internal Medicine4
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
120 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2005. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2003–2005, the window the 2006 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2003–2005 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2006. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 24.88Q1 | 70.14 21.70 up from 2005 | 61 | 100% | $4,330 | ||
2Cancer CellCell Press · Netherlands | 5.96Q1 | 16.92 1.10 up from 2005 | 423 | 99% | $10,400 | ||
3Nature MedicineNature Portfolio · United States | 5.78Q1 | 12.74 1.71 down from 2005 | 1,231 | 15% | $12,690 | ||
4Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 4.74Q1 | 11.33 0.31 up from 2005 | 2,956 | 9% | — | ||
5JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.36Q1 | 11.00 0.68 up from 2005 | 808 | 29% | $5,436 | ||
6JNCI MonographsOxford University Press · United Kingdom | 3.50Q1 | 4.41 1.63 down from 2005 | 96 | 59% | — | ||
7Clinical Pharmacology & TherapeuticsWiley · United States | 3.23Q1 | 6.20 0.31 up from 2005 | 453 | 3% | $4,410 | ||
8The Lancet OncologyElsevier BV · United Kingdom | 2.71Q1 | 6.69 0.66 up from 2005 | 426 | 4% | $7,280 | ||
9Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 2.52Q1 | 6.74 1.08 up from 2005 | 2,280 | 29% | — | ||
10Seminars in Cancer BiologyElsevier BV · United States | 2.50Q1 | 7.50 0.73 up from 2005 | 171 | 8% | $6,060 | ||
11CancerWiley · United States | 2.22Q1 | 4.92 0.18 down from 2005 | 2,481 | 61% | $4,790 | ||
12The OncologistOAAlphaMed Press · United Kingdom | 2.22Q1 | 5.77 0.43 up from 2005 | 323 | 67% | $3,852 | ||
13Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 2.00Q1 | 5.46 0.87 up from 2005 | 408 | 32% | — | ||
14Annals of OncologyElsevier BV · Netherlands | 1.96Q1 | 4.80 0.71 up from 2005 | 1,229 | 95% | $5,080 | ||
15Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 1.91Q1 | 4.13 0.02 up from 2005 | 193 | 0% | — | ||
16British Journal of CancerSpringer Nature · United Kingdom | 1.86Q1 | 5.14 0.30 up from 2005 | 2,076 | 100% | $5,190 | ||
17Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research · United States | 1.86Q1 | 4.86 0.68 up from 2005 | 849 | 34% | — | ||
18European Journal of CancerElsevier BV · United Kingdom | 1.84Q1 | 4.51 0.54 up from 2005 | 1,051 | 7% | $4,270 | ||
19Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.82Q1 | 5.01 1.48 up from 2005 | 288 | 3% | $4,190 | ||
20Psycho-OncologyWiley · United Kingdom | 1.80Q1 | 2.96 0.42 up from 2005 | 299 | 9% | $4,940 | ||
21Seminars in OncologyElsevier BV · United States | 1.74Q1 | 4.13 0.44 down from 2005 | 632 | 1% | $3,550 | ||
22Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.67Q1 | 3.89 1.41 down from 2005 | 215 | 2% | $4,910 | ||
23Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.66Q1 | 3.71 0.21 down from 2005 | 371 | 6% | $3,890 | ||
24International Journal of CancerWiley · United States | 1.65Q1 | 4.32 0.22 down from 2005 | 2,451 | 61% | $5,030 | ||
25Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 1.53Q1 | 4.12 0.05 down from 2005 | 96 | 8% | $4,090 | ||
26Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.52Q1 | 3.36 0.42 up from 2005 | 908 | 3% | — | ||
27JBIC Journal of Biological Inorganic ChemistrySpringer Science+Business Media · Germany | 1.36Q1 | 3.39 0.12 up from 2005 | 322 | 12% | $3,990 | ||
28Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.34Q1 | 3.40 0.21 down from 2005 | 419 | 4% | — | ||
29Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 1.30Q1 | 4.75 1.14 up from 2005 | 194 | 15% | — | ||
30Surgical OncologyElsevier BV · United Kingdom | 1.25Q1 | 2.57 0.26 down from 2005 | 71 | 1% | $3,890 | ||
31Cancer ControlOASAGE Publishing · United States | 1.25Q2 | 2.03 1.42 down from 2005 | 159 | 31% | $2,650 | ||
32Investigational New DrugsSpringer Science+Business Media · Netherlands | 1.22Q2 | 2.67 0.07 down from 2005 | 185 | 4% | $4,690 | ||
33BMC CancerOABioMed Central · United Kingdom | 1.22Q2 | 2.96 0.43 up from 2005 | 294 | 100% | $3,390 | ||
34Cancer NursingLippincott Williams & Wilkins · United States | 1.19Q2 | 1.87 0.34 up from 2005 | 172 | 2% | — | ||
35MicrocirculationWiley · United States | 1.18Q2 | 3.00 0.19 down from 2005 | 186 | 6% | $3,920 | ||
36OncologyKarger Publishers · Switzerland | 1.16Q2 | 2.96 0.52 up from 2005 | 429 | 13% | — | ||
37Supportive Care in CancerSpringer Science+Business Media · Germany | 1.15Q2 | 2.50 0.59 up from 2005 | 429 | 7% | $4,690 | ||
38The Cancer JournalLippincott Williams & Wilkins · United States | 1.14Q2 | 2.12 0.67 down from 2005 | 179 | 2% | — | ||
39Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 1.12Q2 | 2.39 1.06 down from 2005 | 231 | 10% | $5,090 | ||
40Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 1.11Q2 | 2.23 0.02 up from 2005 | 225 | 1% | $3,950 | ||
41Journal of Cancer Research and Clinical OncologyOASpringer Science+Business Media · Germany | 1.10Q2 | 2.81 0.16 up from 2005 | 342 | 100% | $4,390 | ||
42Cancer InvestigationTaylor & Francis · United Kingdom | 1.09Q2 | 2.89 0.80 up from 2005 | 302 | 5% | — | ||
43Journal of Surgical OncologyWiley · United States | 1.08Q2 | 2.52 0.46 up from 2005 | 479 | 7% | $4,570 | ||
44Journal of Inorganic BiochemistryElsevier BV · United States | 1.07Q2 | 2.90 0.41 up from 2005 | 735 | 6% | $4,220 | ||
45European Journal of Cancer PreventionLippincott Williams & Wilkins · United States | 1.06Q2 | 2.22 0.21 up from 2005 | 264 | 0% | — | ||
46European Journal of EpidemiologySpringer Science+Business Media · Italy | 1.05Q2 | 1.98 0.44 up from 2005 | 447 | 11% | $3,690 | ||
47Journal of Clinical PathologyBMJ · United Kingdom | 1.04Q2 | 2.64 0.60 up from 2005 | 875 | 99% | — | ||
48Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.03Q2 | 3.39 0.58 down from 2005 | 468 | 100% | $4,590 | ||
49Breast Cancer ResearchOABioMed Central · United Kingdom | 1.01Q2 | 2.24 0.56 down from 2005 | 703 | 100% | $4,190 | ||
50Drugs of todayProus Science · Spain | 1.00Q2 | 2.52 0.51 up from 2005 | 203 | 1% | — |
Subfields of Medicine, with Oncology highlighted.
- Surgery428
- Pulmonary and Respiratory Medicine181
- Public Health, Environmental and Occupational Health154
- Cardiology and Cardiovascular Medicine150
- Oncology120
- Epidemiology97
- Infectious Diseases95
- Psychiatry and Mental health89
- Radiology, Nuclear Medicine and Imaging86
- Neurology82
- Endocrinology, Diabetes and Metabolism78
- Physiology75
- Orthopedics and Sports Medicine54
- Pediatrics, Perinatology and Child Health54
- Dermatology51
- Hematology48
- Ophthalmology48
- Obstetrics and Gynecology41
- Rheumatology37
- Nephrology34
- Pharmacology29
- Complementary and alternative medicine27
- Reproductive Medicine27
- Emergency Medicine24
- Geriatrics and Gerontology23
- Otorhinolaryngology18
- Rehabilitation18
- Pathology and Forensic Medicine17
- Critical Care and Intensive Care Medicine14
- Immunology and Allergy12
- Genetics9
- Hepatology9
- Anesthesiology and Pain Medicine8
- Urology7
- Gastroenterology6
- Internal Medicine4
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2006. Corpus-wide, 71.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
29 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2003–2005, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2006. Publication window: 2003–2005. How these summaries are calculated
- Ranked journals
- 120
- Window papers (baseline)
- 57,002 +20.3% from indicator year 2003
- Median OJR
- 0.85 +6.7% from indicator year 2003
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2003–2005 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.